Main findings at diagnosis and follow-up data in the entire series and according to bcl-2 protein expression
. | Total (%) . | Bcl-2 negative (%) . | Bcl-2 positive (%) . | P* . |
|---|---|---|---|---|
| No. of cases | 80 | 41 | 39 | |
| Age, y | < .0001 | |||
| Mean | 62 | 52 | 73 | |
| Median | 64 | 48 | 76 | |
| Range | 28-98 | 28-92 | 44-98 | |
| Sex | .002 | |||
| Male | 43 (54) | 29 (71) | 14 (36) | |
| Female | 37 (46) | 12 (29) | 25 (64) | |
| Mean duration before diagnosis, mo | 19 | 25 | 13 | .02 |
| Number of lesions | .5 | |||
| 1 | 32 (40) | 18 (44) | 14 (36) | |
| More than 1 | 48 (60) | 23 (56) | 25 (64) | |
| Site | < .0001 | |||
| Leg | 25 (31) | 3 (7) | 22 (56) | |
| Other sites | 55 (69) | 38 (93) | 17 (44) | |
| Extent | .5 | |||
| Localized | 69 (86) | 36 (88) | 33 (85) | |
| Disseminated | 11 (14) | 5 (12) | 6 (15) | |
| LDH | .15 | |||
| Normal | 72 (90) | 35 (95) | 33 (85) | |
| High | 8 (10) | 2 (5) | 6 (15) | |
| Number of IPI risk factors | < .0001 | |||
| 0 | 28 (35) | 24 (58) | 4 (10) | |
| 1 | 43 (54) | 15 (37) | 28 (72) | |
| 2 | 7 (9) | 2 (5) | 5 (13) | |
| 3 | 2 (2) | 0 (0) | 2 (5) | |
| Morphology | < .0001 | |||
| Cleaved-cell | 48 (60) | 39 (95) | 9 (23) | |
| Round-cell | 32 (40) | 2 (5) | 30 (77) | |
| Initial therapy | .1 | |||
| Radiotherapy (RT) | 41 (51) | 24 (58) | 17 (44) | |
| Chemotherapy† | 21 (26) | 6 (15) | 15 (38) | |
| RT + chemotherapy† | 10 (13) | 5 (12) | 5 (13) | |
| Other | 8 (10) | 6 (15) | 2 (5) | |
| Complete response | .02 | |||
| Yes | 66 (82.5) | 38 (93) | 28 (72) | |
| No | 14 (17.5) | 3 (7) | 11 (28) | |
| Relapse‡ | < .003 | |||
| No | 38 (58) | 26 (68) | 12 (43) | |
| Yes | 28 (42) | 12 (32) | 16 (57) | |
| Extracutaneous progression | < .01 | |||
| No | 59 (74) | 36 (88) | 23 (59) | |
| Yes | 21 (26) | 5 (12) | 16 (41) | |
| Status | < .0001 | |||
| Alive, disease-free | 48 (60) | 36 (88) | 12 (31) | |
| Alive with disease | 2 (3) | 1 (2.5) | 1 (2.5) | |
| Died of lymphoma | 25 (31) | 3 (7) | 22 (56) | |
| Died, other cause | 5 (6) | 1 (2.5) | 4 (10.5) | |
| Specific survival rates, % | < .0001 | |||
| 3-year | 75 | 94 | 55 | |
| 5-year | 65 | 89 | 41 |
. | Total (%) . | Bcl-2 negative (%) . | Bcl-2 positive (%) . | P* . |
|---|---|---|---|---|
| No. of cases | 80 | 41 | 39 | |
| Age, y | < .0001 | |||
| Mean | 62 | 52 | 73 | |
| Median | 64 | 48 | 76 | |
| Range | 28-98 | 28-92 | 44-98 | |
| Sex | .002 | |||
| Male | 43 (54) | 29 (71) | 14 (36) | |
| Female | 37 (46) | 12 (29) | 25 (64) | |
| Mean duration before diagnosis, mo | 19 | 25 | 13 | .02 |
| Number of lesions | .5 | |||
| 1 | 32 (40) | 18 (44) | 14 (36) | |
| More than 1 | 48 (60) | 23 (56) | 25 (64) | |
| Site | < .0001 | |||
| Leg | 25 (31) | 3 (7) | 22 (56) | |
| Other sites | 55 (69) | 38 (93) | 17 (44) | |
| Extent | .5 | |||
| Localized | 69 (86) | 36 (88) | 33 (85) | |
| Disseminated | 11 (14) | 5 (12) | 6 (15) | |
| LDH | .15 | |||
| Normal | 72 (90) | 35 (95) | 33 (85) | |
| High | 8 (10) | 2 (5) | 6 (15) | |
| Number of IPI risk factors | < .0001 | |||
| 0 | 28 (35) | 24 (58) | 4 (10) | |
| 1 | 43 (54) | 15 (37) | 28 (72) | |
| 2 | 7 (9) | 2 (5) | 5 (13) | |
| 3 | 2 (2) | 0 (0) | 2 (5) | |
| Morphology | < .0001 | |||
| Cleaved-cell | 48 (60) | 39 (95) | 9 (23) | |
| Round-cell | 32 (40) | 2 (5) | 30 (77) | |
| Initial therapy | .1 | |||
| Radiotherapy (RT) | 41 (51) | 24 (58) | 17 (44) | |
| Chemotherapy† | 21 (26) | 6 (15) | 15 (38) | |
| RT + chemotherapy† | 10 (13) | 5 (12) | 5 (13) | |
| Other | 8 (10) | 6 (15) | 2 (5) | |
| Complete response | .02 | |||
| Yes | 66 (82.5) | 38 (93) | 28 (72) | |
| No | 14 (17.5) | 3 (7) | 11 (28) | |
| Relapse‡ | < .003 | |||
| No | 38 (58) | 26 (68) | 12 (43) | |
| Yes | 28 (42) | 12 (32) | 16 (57) | |
| Extracutaneous progression | < .01 | |||
| No | 59 (74) | 36 (88) | 23 (59) | |
| Yes | 21 (26) | 5 (12) | 16 (41) | |
| Status | < .0001 | |||
| Alive, disease-free | 48 (60) | 36 (88) | 12 (31) | |
| Alive with disease | 2 (3) | 1 (2.5) | 1 (2.5) | |
| Died of lymphoma | 25 (31) | 3 (7) | 22 (56) | |
| Died, other cause | 5 (6) | 1 (2.5) | 4 (10.5) | |
| Specific survival rates, % | < .0001 | |||
| 3-year | 75 | 94 | 55 | |
| 5-year | 65 | 89 | 41 |